Clinical Research Directory
Browse clinical research sites, groups, and studies.
CEUS Evaluation of Hydrocephalus in Neonates and Infants
Sponsor: Children's Hospital of Philadelphia
Summary
Hydrocephalus affects up to 2 out of every 500 births and results in long-term disability in up to 78% of those affected. The standard treatment of hydrocephalus is cerebrospinal fluid (CSF) diversion via placement of an invasive ventricular shunt to relieve elevated intracranial pressure (ICP). The clinical decision for CSF diversion is based on the ventricular size and clinical symptoms which are not robust indicators of brain health in neonatal hydrocephalus. The purpose of this study is to assess the safety and feasibility of performing brain contrast-enhanced ultrasound (CEUS) in neonates and infants with diagnosed and/or suspected hydrocephalus.
Official title: Pilot Study of Improved Diagnosis and Monitoring of Hydrocephalus in Neonates and Infants Using Contrast-Enhanced Ultrasound
Key Details
Gender
All
Age Range
1 Minute - 18 Months
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2026-03-31
Completion Date
2027-08-01
Last Updated
2026-02-20
Healthy Volunteers
No
Interventions
Sulfur Hexafluoride Lipid Type A Microspheres 25 mg Injection Powder for Suspension [LUMASON]
Injection of Sulfur hexafluoride lipid-type A microspheres contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg before performing the contrast-enhanced ultrasound. The weight-based dose of 0.03 mL per kg will be repeated one time during a single examination. Following each injection, an intravenous flush of 0.9% Sodium Chloride is injected.
Locations (1)
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States